Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

The average drug takes 10+ years and $2.3B to bring to market—with a 90% failure rate in clinical trials. AI is rewriting this equation. By 2025, AI-driven drug discovery is projected to slash ...

Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Musk's tweet comes against the backdrop of an executive order signed by US President Trump, prohibiting federal funding for ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported ...

Moderna (NASDAQ:MRNA) took a hit Tuesday as Barclays downgraded the stock from Overweight to Equal Weight, citing policy ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...